Literature DB >> 6687387

Inactivation of human coagulation factor V by activated protein C.

K Suzuki, J Stenflo, B Dahlbäck, B Teodorsson.   

Abstract

Thrombin-activated vitamin K-dependent protein C purified from human plasma has a potent anticoagulant effect on human plasma, whereas its bovine counterpart has a very weak anticoagulant effect on human plasma. This species difference was found to be partly due to a more rapid degradation of human factor Va by human than by bovine activated protein C. In the presence of phospholipid, activated human protein C cleaves several peptide bonds in fragment D (heavy chain of factor Va), whereas in fragment F1F2 (light chain of factor Va) there appears to be only one peptide bond that is slowly cleaved. The degradation of fragment D is accompanied by a parallel loss of factor V activity. With the blood coagulation factor Xa bound to factor Va, fragment D is protected from degradation by activated protein C, and factor Va remains active. Fragment D isolated from factor Va was exposed to activated protein C in the presence of phospholipid and was found not to be degraded. This observation suggests that fragment D of factor V is bound to phospholipid via fragment F1F2.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6687387

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.

Authors:  Masahiko Okada; Norio Tominaga; Goichi Honda; Junji Nishioka; Nobuyuki Akita; Tatsuya Hayashi; Koji Suzuki; Hiroyuki Moriuchi
Journal:  Blood Adv       Date:  2020-06-23

Review 2.  The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system.

Authors:  M Hessing
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

3.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

4.  Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin.

Authors:  W A Dittman; T Kumada; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains.

Authors:  M Maruno; T Yoshimine; T Isaka; R Kuroda; H Ishii; T Hayakawa
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 6.  The role of endothelium in the pathogenesis of diabetic microangiopathy.

Authors:  M La Selva; E Beltramo; P Passera; M Porta; G M Molinatti
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

7.  Vagus nerve stimulation regulates hemostasis in swine.

Authors:  Christopher J Czura; Arthur Schultz; Martin Kaipel; Anna Khadem; Jared M Huston; Valentin A Pavlov; Heinz Redl; Kevin J Tracey
Journal:  Shock       Date:  2010-06       Impact factor: 3.454

Review 8.  Clinical relevance of protein C.

Authors:  I Pabinger
Journal:  Blut       Date:  1986-08

9.  Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation.

Authors:  C B Glaser; J Morser; J H Clarke; E Blasko; K McLean; I Kuhn; R J Chang; J H Lin; L Vilander; W H Andrews; D R Light
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

10.  Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine474.

Authors:  B Gerlitz; T Hassell; C J Vlahos; J F Parkinson; N U Bang; B W Grinnell
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.